Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89859 | 0.94 | AKT1 (0.42) | AKT1CYP17A1CYP19A1PDE2ACNR1 | |
| SCHEMBL2554955 | 0.84 | AKT1 (0.47) | AKT1CNR1CNR2RAB9AAKT2 | |
| SCHEMBL2143233 | 0.84 | AKT1 (0.41) | AKT1CYP17A1PDE2ACNR1CNR2 | |
| SCHEMBL23778505 | 0.84 | HIF1A (0.39) | CYP19A1PDE2AMAPK1 | |
| SCHEMBL18551335 | 0.83 | MIF (0.46) | AKT1PDE2ACNR1CNR2DRD2 | |
| SCHEMBL23778929 | 0.83 | RAB9A (0.48) | AKT1CYP17A1CYP19A1CNR1CNR2 | |
| SCHEMBL5640967 | 0.82 | AKT1 (0.43) | AKT1PDE2ACNR1CNR2DRD2 | |
| SCHEMBL2588632 | 0.82 | NPC1 (0.47) | AKT1PDE2ARAB9ADRD2AKT2 | |
| SCHEMBL14236180 | 0.82 | AKT1 (0.43) | AKT1PDE2ACNR1CNR2DRD2 | |
| SCHEMBL12196127 | 0.82 | DRD2 (0.53) | AKT1PDE2ACNR1CNR2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363686-A1 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-11-17 | — | — | US | disclosed |
| US-20210355129-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3873909-A1 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3873908-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2021-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363686-A1 | NOVEL 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | AKT1 1862/4885CYP17A1 4347/4885CYP19A1 3395/4885 |
| US-20210355129-A1 | NOVEL UREA 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, CDKN1A | AKT1 2165/4885CYP17A1 4047/4885CYP19A1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.